Company Analysis
Sign in

Supernus Pharmaceuticals, Inc. (SUPN)

SUPN · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2006
Full chart Alerts Compare
Grade5.9
◀ Past 5.2● Present 7.1▶ Future 5.0
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

206 patents granted to the 9 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Supernus Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
206
206 utility, 1976 to Dec 31, 2025
Granted in 2025
14
Against 28 in 2024 and 13 in 2023
Applications published
442
43 of them in 2025
Names they are printed under
9
a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals47
Organic fine chemistry36
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name9 counted
Sage Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
219 published
Supernus Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
80 granted
115 published
Sage Therapeutics, LLP a subsidiary
US, as the owner printed on each patent
93 granted
16 published
Adamas Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
31 granted
27 published
Adamas Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
51 published
Supernus Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
10 published
Biscayne Neurotherapeutics, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
2 published
Adamas Pharmaceuticals, Inc. a Delaware Corporation a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Biscayne Neurotherapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,502,356Use of higher doses of modified release huperzine formulationsPharmaceuticalsBiscayne Neurotherapeutics, Inc.
Nov 18, 202512,473,327Neuroactive steroids, compositions and uses thereofOrganic fine chemistrySage Therapeutics, LLP
Oct 28, 202512,454,535Substituted derivatives of isoindolesOrganic fine chemistrySupernus Pharmaceuticals, Inc.
Oct 21, 202512,448,409Oxysterols and methods of use thereofPharmaceuticalsSage Therapeutics, LLP
Sep 23, 202512,421,275Compositions and methods for treating CNS disordersOrganic fine chemistrySage Therapeutics, LLP
Sep 9, 202512,410,210Neuroactive steroids and their methods of useOrganic fine chemistrySage Therapeutics, LLP
Jul 15, 202512,358,942Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroidPharmaceuticalsSage Therapeutics, LLP
Jun 17, 202512,331,070C7 substituted oxysterols and methods of use thereofPharmaceuticalsSage Therapeutics, LLP
May 27, 202512,311,060Modified release pharmaceutical compositions of huperzine and methods of using the samePharmaceuticalsBiscayne Neurotherapeutics, Inc.
Apr 8, 202512,268,697Oxysterols and methods of use thereofPharmaceuticalsSage Therapeutics, LLP
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388622C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOFOrganic fine chemistrySage Therapeutics, Inc.
Dec 25, 20252025/038741419-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOFPharmaceuticalsSage Therapeutics, Inc.
Dec 25, 20252025/0387413OXYSTEROLS AND METHODS OF USE THEREOFOrganic fine chemistrySage Therapeutics, Inc.
Dec 4, 20252025/0367208FORMULATIONS OF VILOXAZINEPharmaceuticalsSupernus Pharmaceuticals, Inc.
Nov 6, 20252025/033944719-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOFPharmaceuticalsSage Therapeutics, Inc.
Oct 23, 20252025/0326784OXYSTEROLS AND METHODS OF USE THEREOFOrganic fine chemistrySage Therapeutics, Inc.
Oct 16, 20252025/031910619-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOFOrganic fine chemistrySage Therapeutics, Inc.
Oct 16, 20252025/0319105NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASEPharmaceuticalsSage Therapeutics, Inc.
Oct 2, 20252025/0304615CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDPharmaceuticalsSage Therapeutics, Inc.
Sep 25, 20252025/0295674NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERSPharmaceuticalsSage Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 45 · Organic fine chemistry 33 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SUPN · research, not advice